{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon+Infusion", "query": { "intervention": "Glucagon Infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon+Infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T03:49:36.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06126354", "title": "Dexamethasone/Pancreatic Clamp P&F", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Prediabetic State", "Non-Alcoholic Fatty Liver Disease", "Overweight and Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Human Growth Hormone", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "OTHER" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" }, { "name": "Normal saline", "type": "OTHER" }, { "name": "Human albumin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2024-07-01", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126354" }, { "nct_id": "NCT03139305", "title": "Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Glucagon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AdventHealth Translational Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2017-10-24", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139305" }, { "nct_id": "NCT05724134", "title": "Pancreatic Clamp in NAFLD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Prediabetic State", "Hyperinsulinemia", "Non-Alcoholic Fatty Liver Disease", "Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Growth Hormone, Human", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "OTHER" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "CORE Bar", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2023-08-29", "completion_date": "2025-09-24", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05724134" }, { "nct_id": "NCT01951716", "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Does the Vagus Nerve Mediate the Effects of Xenin-25" ], "interventions": [ { "name": "Graded Glucose Infusion with Placebo", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP Alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with xenin-25 alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP plus xenin-25", "type": "DRUG" }, { "name": "Meal Tolerance Test with Placebo", "type": "DRUG" }, { "name": "Meal Tolerance Test with xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951716" }, { "nct_id": "NCT01552603", "title": "Artificial Pancreas Control System in an Inpatient Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type I Diabetes Mellitus" ], "interventions": [ { "name": "Artificial Pancreas Control Software", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Legacy Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2012-03", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 2, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552603" }, { "nct_id": "NCT02748369", "title": "In Vivo Assessment of Cellular Metabolism in Humans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Normal Cellular Metabolism" ], "interventions": [ { "name": "Somatostatin", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K. Sreekumaran Nair", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 17, "start_date": "2016-07", "completion_date": "2017-03-02", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748369" }, { "nct_id": "NCT05375968", "title": "Splanchnic Venous Capacitance in Postural Tachycardia Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postural Tachycardia Syndrome (POTS)" ], "interventions": [ { "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients", "type": "DIAGNOSTIC_TEST" }, { "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls", "type": "DIAGNOSTIC_TEST" }, { "name": "Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2", "type": "DRUG" }, { "name": "Compare change is SVC and SMA flow due to saline", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 50, "start_date": "2023-02-25", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375968" }, { "nct_id": "NCT02733588", "title": "Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypoglycemia", "Complications of Bariatric Procedures" ], "interventions": [ { "name": "G-Pump™ (glucagon infusion)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xeris Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2016-03", "completion_date": "2017-06-01", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02733588" }, { "nct_id": "NCT03490942", "title": "Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypoglycemia Unawareness", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Glucagon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xeris Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "21 Years to 64 Years" }, "enrollment_count": 49, "start_date": "2018-03-15", "completion_date": "2020-02-10", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 5, "location_summary": "Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03490942" }, { "nct_id": "NCT01511185", "title": "Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2001-02", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2017-01-26", "last_synced_at": "2026-09-05T03:49:36.180Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01511185" } ] }